Trial Profile
A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 18 Mar 2022 Status changed from active, no longer recruiting to completed.
- 27 Jan 2022 Planned End Date changed from 31 Dec 2021 to 28 Feb 2022.
- 14 Oct 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2021.